Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company, is committed to developing and commercializing innovative small molecule drugs for the treatment of cancer. Pralatrexate (PDX), the Company’s lead product candidate, is a novel antifolate currently in a pivotal Phase 2 (PROPEL) trial. RH1, a targeted chemotherapeutic agent, is Allos Therapeutics’ other product candidate and is currently being evaluated in a Phase 1 trial. For further information, visit the Company’s web site at www.allos.com.
- 18 years ago
QualityStocks
Allos Therapeutics, Inc. (NASDAQ: ALTH)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory…
-
Wrap Technologies Inc. (NASDAQ: WRAP) Positions Non-Lethal Innovation at the Center of Public Safety Reform
WRAP offerings illustrate a broader industry trend toward building connected ecosystems rather than standalone products.…
-
Brownfield Gold Projects Could Hold an Edge in Today’s Permitting Environment
Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.…